TY - JOUR
T1 - Pronounced antibody elevation after SARS-CoV-2 BNT162b2 mRNA booster vaccination in nursing home residents
AU - Chong, Yong
AU - Goto, Takeyuki
AU - Tani, Naoki
AU - Yonekawa, Akiko
AU - Ikematsu, Hideyuki
AU - Shimono, Nobuyuki
AU - Tanaka, Yosuke
AU - Akashi, Koichi
N1 - Funding Information:
First, we would like to thank Atsushi Hisaeda and Seiji Sasaki for their technical support. Next, we sincerely thank Junko Nakahara and Yoko Ikeda for all of their support in the investigation. We would also like to thank the entire Department of Clinical Chemistry (Kanenokuma Hospital), including Tomoyuki Fukamachi. Finally, we thank all staff members of the facility for their dedicated work.
Publisher Copyright:
© 2022 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
PY - 2022/11
Y1 - 2022/11
N2 - Background: Infection control during COVID-19 outbreaks in nursing facilities is a critical public health issue. Antibody responses before and after the third (booster) dose of SARS-CoV-2 vaccination in nursing home residents have not been fully characterized. Methods: This study included 117 individuals: 54 nursing home residents (mean age, 83.8 years; 39 SARS-CoV-2-naive and 15 previously infected) and 63 healthcare workers (mean age, 45.8 years; 32 SARS-CoV-2-naive and 31 previously infected). Anti-spike (receptor-binding domain [RBD]) and anti-nucleocapsid antibody responses to BNT162b2 mRNA vaccination and their related factors were evaluated using pre- (shortly and 6 months after the second dose) and post-booster vaccination samples. Results: The median anti-spike (RBD) IgG level in SARS-CoV-2-naive residents 6 months after the second dose was the lowest among the four groups, with a decreasing rate of over 90%. The median rate of increase before and after the third dose in SARS-CoV-2-naive residents was significantly higher than that in SARS-CoV-2-naive healthcare workers (64.1- vs. 37.0-fold, P = 0.003), with the highest level among the groups. The IgG ratio of SARS-CoV-2-naive residents to healthcare workers after the second and third doses changed from one-fifth (20%) to one-half (50%). The rate of increase after the third dose in previously infected individuals was three- to fourfold, regardless of residents or healthcare workers. Conclusions: Advanced aged nursing home residents, poor responders in the initial SARS-CoV-2 vaccine series, could obtain sufficient antibody responses with the additional booster dose, despite more than 6 months after the second.
AB - Background: Infection control during COVID-19 outbreaks in nursing facilities is a critical public health issue. Antibody responses before and after the third (booster) dose of SARS-CoV-2 vaccination in nursing home residents have not been fully characterized. Methods: This study included 117 individuals: 54 nursing home residents (mean age, 83.8 years; 39 SARS-CoV-2-naive and 15 previously infected) and 63 healthcare workers (mean age, 45.8 years; 32 SARS-CoV-2-naive and 31 previously infected). Anti-spike (receptor-binding domain [RBD]) and anti-nucleocapsid antibody responses to BNT162b2 mRNA vaccination and their related factors were evaluated using pre- (shortly and 6 months after the second dose) and post-booster vaccination samples. Results: The median anti-spike (RBD) IgG level in SARS-CoV-2-naive residents 6 months after the second dose was the lowest among the four groups, with a decreasing rate of over 90%. The median rate of increase before and after the third dose in SARS-CoV-2-naive residents was significantly higher than that in SARS-CoV-2-naive healthcare workers (64.1- vs. 37.0-fold, P = 0.003), with the highest level among the groups. The IgG ratio of SARS-CoV-2-naive residents to healthcare workers after the second and third doses changed from one-fifth (20%) to one-half (50%). The rate of increase after the third dose in previously infected individuals was three- to fourfold, regardless of residents or healthcare workers. Conclusions: Advanced aged nursing home residents, poor responders in the initial SARS-CoV-2 vaccine series, could obtain sufficient antibody responses with the additional booster dose, despite more than 6 months after the second.
UR - http://www.scopus.com/inward/record.url?scp=85135850801&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135850801&partnerID=8YFLogxK
U2 - 10.1111/irv.13030
DO - 10.1111/irv.13030
M3 - Article
C2 - 35962568
AN - SCOPUS:85135850801
SN - 1750-2640
VL - 16
SP - 1066
EP - 1071
JO - Influenza and other Respiratory Viruses
JF - Influenza and other Respiratory Viruses
IS - 6
ER -
